Sfoglia per Autore
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up
2022-01-01 Rolla S.; De Mercanti S.F.; Bardina V.; Maglione A.; Taverna D.; Novelli F.; Cocco E.; Vladic A.; Habek M.; Adamec I.; Annovazzi P.O.L.; Horakova D.; Clerico M.
Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis
2019-01-01 Andrea Iannello, Simona Rolla, Alessandro Maglione, Giulio Ferrero, Valentina Bardina, Ilenia Inaudi, Stefania De Mercanti, Francesco Novelli, Lucrezia D'Antuono, Simona Cardaropoli, Tullia Todros, Maria Vittoria Turrini, Cinzia Cordioli, Giorgia Puorro, Angela Marsili, Roberta Lanzillo, Vincenzo Brescia Morra, Francesca Cordero, Michele De Bortoli, Luca Durelli, Andrea Visconti, Santina Cutrupi, Marinella Clerico
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study
2018-01-01 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M
Epigenetic signature in T helper 17 and regulatory T cells in multiple sclerosis patients during pregnancy
2018-01-01 Andrea Iannello, Alessandro Maglione, Giulio Ferrero, Simona Rolla, Valentina Bardina, Francesca Cordero, Michele De Bortoli, Marinella Clerico, Santina Cutrupi
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis.
2018-01-01 Rolla Simona, Bardina Valentina, Iannello Andrea, Maglione Alessandro, De Mercanti Stefania, Puorro Giorgia, Lanzillo Roberta, Cordioli Cinzia, Turrini Mariavittoria, De Bortoli Michele, Cutrupi Santina, Clerico Marinella.
Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome
2018-01-01 Rolla, S; Ferrocino, I; Bardina, V; Ferraro, M; Cianflone, A; Lanzillo, R; De Mercanti, S; Cocolin, L; Clerico, M
Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity
2017-01-01 Alchera, E;Rolla, S; Imarisio, C; Bardina, V; Valente, G; Novelli, F; Carini, R
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation
2017-01-01 Iannello A., Ferrero G., Maglione A., Cordero F., Rolla S., Bardina V., De Mercanti S., Durelli L., Clerico M., Cutrupi S.
Six year prospective immunological study of alemtuzumab treated patients: identification of markers of the clinical response
2017-01-01 Durelli, L; Rolla, S; De Mercanti, S; Bardina, V; Cucci, A; Taverna, D; Novelli, F; Cocco, E; Vladic, A; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Clerico, M
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis
2017-01-01 Clerico M.; Artusi C.A.; Di Liberto A.; Rolla S.; Bardina V.; Barbero P.; De Mercanti S.F.; Durelli L.
Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study
2017-01-01 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Ferraro, M; Cianflone, A; Lanzillo, R; Durelli, L; Cocolin, LS; Clerico, M
Natalizumab in Multiple Sclerosis: Long-Term Management
2017-01-01 Clerico, Marinella; Artusi, Carlo; Di Liberto, Alessandra; Rolla, Simona; Bardina, Valentina; Barbero, Pierangelo; De Mercanti, Stefania Federica; Durelli, Luca
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
2017-01-01 Rolla, Simona; De Mercanti, Stefania Federica; Bardina, Valentina; Horakova, Dana; Habek, Mario; Adamec, Ivan; Cocco, Eleonora; Annovazzi, Pietro; Vladic, Anton; Novelli, Francesco; Durelli, Luca; Clerico, Marinella
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study
2017-01-01 Clerico, M; Signori, A; De Mercanti, S; Artusi, CA; Maniscalco, GT; Carotenuto, A; Lanzillo, R; Esposito, S; Capuano, R; Bonavita, S; Lorefice, L; Cocco, E; Annovazzi, P; Baroncini, D; Zaffaroni, M; Vercellino, M; Trebini, C; Cavalla, P; Clerici, VT; Bardina, V; Rolla, S; Durelli, L; Sormani, MP
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation
2016-01-01 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice
2016-01-01 Rolla, Simona; Alchera, Elisa; Imarisio, Chiara; Bardina, Valentina; Valente, Guido; Cappello, Paola; Mombello, Cristina; Follenzi, Antonia; Novelli, Francesco; Carini, Rita
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months
2016-01-01 De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months
2016-01-01 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment
2015-01-01 De Mercanti, S.F.; Rolla, S.; Cucci, A.; Bardina, V.; Vacca, A.; Cocco, E.; Vladic, A.; Soldo-Butkovic, S.; Habek, M.; Adamec, I.; Horakova, D.; Annovazzi, P.; Edan, G.; Novelli, F.; Durelli, L.; Clerico, M.
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function
2015-01-01 De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Vacca, A; Cocco, E; Vladic, A; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Edan, G; Durelli, L; Clerico, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up | 2022 | Rolla S.; De Mercanti S.F.; Bardina V.; Maglione A.; Taverna D.; Novelli F.; Cocco E.; Vladic A.; Habek M.; Adamec I.; Annovazzi P.O.L.; Horakova D.; Clerico M. | |
| Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis | 2019 | Andrea Iannello, Simona Rolla, Alessandro Maglione, Giulio Ferrero, Valentina Bardina, Ilenia Inaudi, Stefania De Mercanti, Francesco Novelli, Lucrezia D'Antuono, Simona Cardaropoli, Tullia Todros, Maria Vittoria Turrini, Cinzia Cordioli, Giorgia Puorro, Angela Marsili, Roberta Lanzillo, Vincenzo Brescia Morra, Francesca Cordero, Michele De Bortoli, Luca Durelli, Andrea Visconti, Santina Cutrupi, Marinella Clerico | |
| Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study | 2018 | Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M | |
| Epigenetic signature in T helper 17 and regulatory T cells in multiple sclerosis patients during pregnancy | 2018 | Andrea Iannello, Alessandro Maglione, Giulio Ferrero, Simona Rolla, Valentina Bardina, Francesca Cordero, Michele De Bortoli, Marinella Clerico, Santina Cutrupi | |
| Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis. | 2018 | Rolla Simona, Bardina Valentina, Iannello Andrea, Maglione Alessandro, De Mercanti Stefania, Puorro Giorgia, Lanzillo Roberta, Cordioli Cinzia, Turrini Mariavittoria, De Bortoli Michele, Cutrupi Santina, Clerico Marinella. | |
| Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome | 2018 | Rolla, S; Ferrocino, I; Bardina, V; Ferraro, M; Cianflone, A; Lanzillo, R; De Mercanti, S; Cocolin, L; Clerico, M | |
| Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity | 2017 | Alchera, E;Rolla, S; Imarisio, C; Bardina, V; Valente, G; Novelli, F; Carini, R | |
| Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation | 2017 | Iannello A., Ferrero G., Maglione A., Cordero F., Rolla S., Bardina V., De Mercanti S., Durelli L., Clerico M., Cutrupi S. | |
| Six year prospective immunological study of alemtuzumab treated patients: identification of markers of the clinical response | 2017 | Durelli, L; Rolla, S; De Mercanti, S; Bardina, V; Cucci, A; Taverna, D; Novelli, F; Cocco, E; Vladic, A; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Clerico, M | |
| Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis | 2017 | Clerico M.; Artusi C.A.; Di Liberto A.; Rolla S.; Bardina V.; Barbero P.; De Mercanti S.F.; Durelli L. | |
| Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study | 2017 | Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Ferraro, M; Cianflone, A; Lanzillo, R; Durelli, L; Cocolin, LS; Clerico, M | |
| Natalizumab in Multiple Sclerosis: Long-Term Management | 2017 | Clerico, Marinella; Artusi, Carlo; Di Liberto, Alessandra; Rolla, Simona; Bardina, Valentina; Barbero, Pierangelo; De Mercanti, Stefania Federica; Durelli, Luca | |
| Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses | 2017 | Rolla, Simona; De Mercanti, Stefania Federica; Bardina, Valentina; Horakova, Dana; Habek, Mario; Adamec, Ivan; Cocco, Eleonora; Annovazzi, Pietro; Vladic, Anton; Novelli, Francesco; Durelli, Luca; Clerico, Marinella | |
| How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study | 2017 | Clerico, M; Signori, A; De Mercanti, S; Artusi, CA; Maniscalco, GT; Carotenuto, A; Lanzillo, R; Esposito, S; Capuano, R; Bonavita, S; Lorefice, L; Cocco, E; Annovazzi, P; Baroncini, D; Zaffaroni, M; Vercellino, M; Trebini, C; Cavalla, P; Clerici, VT; Bardina, V; Rolla, S; Durelli, L; Sormani, MP | |
| Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation | 2016 | Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M | |
| The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice | 2016 | Rolla, Simona; Alchera, Elisa; Imarisio, Chiara; Bardina, Valentina; Valente, Guido; Cappello, Paola; Mombello, Cristina; Follenzi, Antonia; Novelli, Francesco; Carini, Rita | |
| Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months | 2016 | De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella | |
| Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months | 2016 | Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M | |
| T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment | 2015 | De Mercanti, S.F.; Rolla, S.; Cucci, A.; Bardina, V.; Vacca, A.; Cocco, E.; Vladic, A.; Soldo-Butkovic, S.; Habek, M.; Adamec, I.; Horakova, D.; Annovazzi, P.; Edan, G.; Novelli, F.; Durelli, L.; Clerico, M. | |
| Long Term immunological alemtuzumab effect: increase in Tregsuppressor function | 2015 | De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Vacca, A; Cocco, E; Vladic, A; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Edan, G; Durelli, L; Clerico, M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile